Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A, Valsecchi L, Quadri M, Watrin T, Scharov K, Procopio S, Tu JW, Vogt M, Savino AM, Silvestri D, Valsecchi MG, Biondi A, Borkhardt A, Bhatia S, Cazzaniga G, Fazio G, Bardini M, Palmi C. Oikonomou A, et al. Among authors: watrin t. Biochem Pharmacol. 2023 Nov;217:115809. doi: 10.1016/j.bcp.2023.115809. Epub 2023 Sep 17. Biochem Pharmacol. 2023. PMID: 37717691 Free article.
Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma.
Schedel A, Friedrich UA, Morcos MNF, Wagener R, Mehtonen J, Watrin T, Saitta C, Brozou T, Michler P, Walter C, Försti A, Baksi A, Menzel M, Horak P, Paramasivam N, Fazio G, Autry RJ, Fröhling S, Suttorp M, Gertzen C, Gohlke H, Bhatia S, Wadt K, Schmiegelow K, Dugas M, Richter D, Glimm H, Heinäniemi M, Jessberger R, Cazzaniga G, Borkhardt A, Hauer J, Auer F. Schedel A, et al. Among authors: watrin t. Int J Mol Sci. 2022 May 5;23(9):5174. doi: 10.3390/ijms23095174. Int J Mol Sci. 2022. PMID: 35563565 Free PMC article.
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB, Vallera DA, Manser AR, Watrin T, Bhatia S, Felices M, Miller JS, Uhrberg M, Babor F. Reusing SB, et al. Among authors: watrin t. Cancer Immunol Immunother. 2021 Dec;70(12):3709. doi: 10.1007/s00262-021-03040-0. Cancer Immunol Immunother. 2021. PMID: 34491408 Free PMC article. No abstract available.